Navigation Links
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Date:11/4/2008

short stature associated with Turner Syndrome, treatment of children with growth failure due to inadequate secretion of endogenous growth hormone, and treatment of short stature in children born SGA with no catch-up growth by age 2. It is also indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD) who meet either of the following two criteria:

1) Adult Onset: Patients who have GHD, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or

2) Childhood Onset: Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

According to current standards, confirmation of the diagnosis of adult growth hormone deficiency in both groups involves an appropriate growth hormone provocative test with two exceptions: (1) patients with multiple other pituitary hormone deficiencies due to organic disease; and (2) patients with congenital/genetic growth hormone deficiency.

Important Safety Information

Remember, your doctor is the main source of information about you and your health. Please consult your doctor if you have any questions about your health or your medication.

Norditropin(R) (somatropin [rDNA origin] injection) is used to treat children with growth failure caused by very low or no production of growth hormone. It is also used to treat adults who do not make enough growth hormone.

Do not use Norditropin(R) if you have any of the following conditions: an allergy to phenol or any other ingredients in the medicine; active cancer or other forms of tumor; acute critical illness due to certain types of heart or abdomen surgery, trauma, or acute respiratory failure.

Children should not use Norditropin(R) if they have any of the following conditions: closed epiphyses (closed bone growth plates
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves Durameds LoSEASONIQUE(R) Oral Contraceptive
2. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
3. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
4. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
5. FDA Approves Fougeras Clotrimazole Cream USP 1%
6. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
7. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
8. Signalife Board Approves Merger
9. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
10. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
11. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... $5.8 million and provides a good start to Q4.  The orders ... and one in the Middle East ... levels," said Peter Bruijns , President & CEO. "Total bidding ... than they have been for any complete year since the company ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... , ORANGE COUNTY, Calif., July 27 ... Board of Directors declared a quarterly dividend payout of seventeen cents ($0.17) ... all stockholders of record on August 10, 2009. This payout represents ... (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) , , Beckman Coulter, Inc., ...
... , , , ... Calif. and LONDON, July 27 Amgen (Nasdaq: AMGN ... companies will share commercialization of Amgen,s monoclonal antibody denosumab for postmenopausal ... product is approved in these countries. Amgen will commercialize the ...
... , , , ... ZMH ; SWX: ZMH) today announced the launch of ... with teaching surgeons and subject matter experts to develop a unique ... Training and Surgeon-to-Surgeon programs under one, consolidated service offering, the enhanced ...
Cached Biology Technology:Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 7Zimmer Launches New Medical Education and BioSkills Training Program 2Zimmer Launches New Medical Education and BioSkills Training Program 3Zimmer Launches New Medical Education and BioSkills Training Program 4
(Date:10/16/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market announces that ... Smart Wallet, at the 13 th annual Future ... conference on the intersection of technology and the economy. ... founder and publisher of the Strategic News Service™, the ...
(Date:10/15/2014)... our ability to assess the pandemic risk from strains ... we must not allow ourselves to become complacent that ... international consortium of scientists. , Influenza pandemics arise when ... yet to develop widespread immunity – spreads in the ... the past 100 years, the worst of which – ...
(Date:10/15/2014)... Gauß-Allianz has admitted Johannes Gutenberg University Mainz (JGU) ... science hub continues to maintain a significant nationwide ... , "The acceptance of Johannes Gutenberg University Mainz ... a milestone in the national and international competition ... state of Rhineland-Palatinate can be proud that Mainz ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... in Nature , researchers at Brandeis University and the ... time shed light on a crucial step in the complex ... in the human cell and frequently at which point genetic ... they were able to crystallize a very large complex of ...
... does inflammation, brought on by stress, affect aging? What can ... crisis of an epidemic of neurologic diseases caused by a ... keep a rosy outlook in the face of inevitable decline? ... host of other questions are the focus of the inaugural ...
... Hughes Medical Research Institute today announced that two researchers ... scientists nationwide to be appointed HHMI Early Career Scientists. ... of the Center,s Basic Sciences Division, and Toshiyasu Taniguchi, ... Biology and Public Health Sciences divisions, each will receive ...
Cached Biology News:A splice of life 2Living long, living well 2Two Hutchinson Center researchers named HHMI Early Career Scientists 2
Synaptic Vesicle I Sampler Kit 10g each...
Handles samples from from 75l to 150l...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Mouse monoclonal [N7519] to NR0B2 ( Abpromise for all tested applications). Antigen: E.coli expressed recombinant full length protein (Human) NR0B2 Entrez Gene ID: 8431 Swiss Protein ID: ...
Biology Products: